Llwytho...

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides and macrocycles (2015–2018)

INTRODUCTION: The protein protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs. More...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Expert Opin Ther Pat
Prif Awduron: Shaabani, Shabnam, Huizinga, Harmen P.S., Butera, Roberto, Kouchi, Ariana, Guzik, Katarzyna, Magiera-Mularz, Katarzyna, Holak, Tad A., Dömling, Alexander
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6323140/
https://ncbi.nlm.nih.gov/pubmed/30107136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543776.2018.1512706
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!